 |
1 Product |  |
0 Diseases | | 1 Product |
|
0 Trials |  |
71 News |  |
- || granisetron transdermal (SyB-0701) / Synmosa Biopharma, SymBio, Abeille Pharma
Retrospective data, Review, Journal, CINV: Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis. (Pubmed Central) - Jan 26, 2021
Oral granisetron is better in achieving complete control of CINV in patients receiving chemotherapy. As for the risk of constipation and QTc prolongation as adverse effects, there was no statistically significant difference between the two routes.
- ||| Sancuso (granisetron) / Kyowa Kirin, Solasia
Clinical, P3 data, Journal: A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. (Pubmed Central) - Dec 30, 2020
Transdermal granisetron was 82% more like to control CINV than oral ondansetron in the late phase of cycle 1 and performed similarly to oral ondansetron in all other cycles. Transdermal granisetron should be considered an option as prophylactic antiemetic therapy for gynecologic cancer survivors undergoing chemoradiation.
- Sancuso (granisetron) / Kyowa Hakko Kirin, Solasia
[VIRTUAL] Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1407;
Some previous cases receiving multiday highly emetogenic chemotherapy (HEC) regimens showed that the GTDS plus dexamethasone was not inferior to the GTDS plus dexamethasone and aprepitant...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Sancuso (granisetron) / Kyowa Hakko Kirin, Solasia
[VIRTUAL] Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1043;
Some previous cases receiving multiday highly emetogenic chemotherapy (HEC) regimens showed that the GTDS plus dexamethasone was not inferior to the GTDS plus dexamethasone and aprepitant...Our study indicate that the two regimens therapy provides effective, well-tolerated control of multiday HEC. It offers a alternative route for delivering two regimens for up to 7 days that is as effective as three regimens.
- Sancuso (granisetron) / Kyowa Hakko Kirin, Solasia
[VIRTUAL] Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_677;
Some previous cases receiving multiday highly emetogenic chemotherapy (HEC) regimens showed that the GTDS plus dexamethasone was not inferior to the GTDS plus dexamethasone and aprepitant...Our study indicate that the two regimens therapy provides effective, well-tolerated control of multiday HEC. It offers a alternative route for delivering two regimens for up to 7 days that is as effective as three regimens.
- | granisetron oral / generics
Clinical, PK/PD data, Journal: Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects: An open-label, randomized, crossover study. (Pubmed Central) - Aug 7, 2019
The C values determined through TD and OA were equivalent, indicating similar drug exposures. Therefore, the granisetron patch may be an alternative formulation for oral granisetron in Chinese individuals..
- |||| granisetron transdermal (SyB-0701) / Synmosa Biopharma, SymBio, Abeille Pharma
Trial completion: Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV) (clinicaltrials.gov) - Nov 19, 2014
P2, N=189, Completed, Sponsor: SymBio Pharmaceuticals
Therefore, the granisetron patch may be an alternative formulation for oral granisetron in Chinese individuals.. Recruiting --> Completed
- granisetron transdermal (SyB-0701) / Synmosa Biopharma, SymBio, Abeille Pharma
New P2 trial: Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV) (clinicaltrials.gov) - Oct 2, 2012
P2, N=0, Recruiting, Sponsor: SymBio Pharmaceuticals